CoChat

DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay

Open access
Zangene, Ehsan, Gholizadeh, Elham, Schwämmle, Veit, Saei, Amir Ata, Wilhelm, Mathias, Käll, Lukas, Jafari, Mohieddin · 2026 · Molecular & Cellular Proteomics

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; none of the 44 sources its claims cite is checked for support yet.

Abstract

Advancements in high-throughput techniques such as Thermal Proteome Profiling and the high-throughput Proteome Integral Solubility Alteration assay have revolutionized our understanding of drug-protein interactions. Despite these innovations, the absence of an integrative platform for cross-study analysis of stability and solubility alteration data represents a significant bottleneck. To address this gap, we introduce Drug-target interactOmics Resource based on Stability/Solubility Alteration Assay (DORSSAA), an interactive and expandable web-based platform for the systematic analysis and visualization of proteome stability and solubility alteration assay datasets. Currently, DORSSAA features 1,135,985 records spanning 38 cell lines and organisms, 135 compounds, and 40,742 protein targets. Through its user-friendly interface, the resource supports comparative drug-protein interaction analysis and facilitates the discovery of actionable therapeutic targets. Through two case studies, methotrexate target profiling in A549 cells and combinatorial-therapy drug-target interactions in leukemia cell lines, we demonstrate DORSSAA's utility for identifying protein-drug interactions across diverse experimental contexts. This resource empowers researchers to accelerate drug discovery and enhance our understanding of protein behavior. Compared with data repositories and interaction databases, DORSSAA provides direct protein-level evidence of mechanisms of action with strict statistical control for each study. This enables more reliable identification of drug targets, off-target effects, and potential drug combinations.

Overview

CoChat Summary

TL;DR

DORSSAA is an interactive web resource integrating TPP/PISA-family stability and solubility alteration datasets for drug-target interactomics, containing 1,135,985 records across 38 cell lines/organisms, 135 compounds, and 40,742 protein targets. It supports context-aware, cross-study exploration of drug-protein interactions, demonstrated through case studies on methotrexate-DHFR, sapanisertib-H2AFX in AML lines, and SCIN compound retrieval.

Key findings

  • DORSSAA contains 1,135,985 drug-protein interaction records spanning 38 cell lines and organisms, 135 compounds, and 40,742 protein targets (as of 25 October 2025), harmonized from 24 publicly available thermal-shift proteomics datasets covering TPP, PISA, and i-PISA, together with an in-house CoPISA dataset.
  • In a methotrexate/A549 cell-lysate proof-of-principle query, DHFR (UniProt P00374) was among 15 target records, showed the highest log2-fold change with a significant FDR at threshold 0.05, and was linked in the Compound Query tab to five additional compounds including staurosporine, SNS032, raltitrexed, and panobinostat.
  • In an AML case study, sapanisertib was associated with an H2AFX stability shift in MOLM-16 (log2 fold change = −1.673; FDR = 0.03993) and in SKM-1 (log2 fold change = +1.533; p = 0.010); the Ruxolitinib + Ulixertinib combination showed a log2 fold change = 0.986; p = 0.011, presented as hypothesis-generating pathway-level observations.
  • In an exploratory SCIN case study, K562 was the strongest available context; nine candidate compounds were retrieved at p ≤ 0.05, with sotrastaurin ranked first (p = 0.005; FC = −0.221), and the Meltome layer reported SCIN melting points in the range of 45 to 50 °C.

Methods

  • The authors assembled a harmonized corpus of 24 publicly available thermal-shift proteomics datasets covering TPP, PISA, and i-PISA, plus an in-house CoPISA dataset, spanning 135 small molecules across 38 cancer cell lines or species; treatment context (intact cells vs. lysate/extract) was preserved as study-level metadata.
  • Data were reshaped to tidy long format with metadata including PMID, compound, cell line, UniProt ID, gene symbol, replicate, concentration, effect size, and statistical fields; compounds were linked to PubChem InChIKeys, cell lines annotated with Cellosaurus and organism information, and a coverage map plus normalized interaction fact table were materialized into an indexed SQL backend.
  • Statistical harmonization converted reported −log10(p) values back to raw p-values where needed, controlled multiple testing within study-defined families per (PMID × compound) using Storey q-values with Benjamini–Yekutieli fallback, used an empirical DMSO-null framework for the K562 PISA study with per-drug Benjamini–Hochberg FDR, and did not apply a single global FDR; the web application was built in R/Shiny with DBI SQL and JavaScript.

Limitations

  • The paper states that DORSSAA is not a formal cross-assay benchmarking analysis; differences in assay chemistry, sample type, temperature regime, compound exposure, proteome depth, and statistical processing may influence target detection, ranking, and cross-study reproduction, so it should be viewed as a harmonized exploration and hypothesis-generation resource rather than definitive evidence of full assay-to-assay comparability.
  • The paper states that p-values and effect sizes are useful for within-study filtering and exploratory cross-study contextualization but should not be treated as universally interchangeable quantitative measures; DORSSAA does not provide a cumulative global false-discovery rate, and cross-study recurrence is hypothesis-generating. It also includes both lysate/extract-based and intact-cell datasets, which should not be interpreted interchangeably, and intact-cell observations should not automatically be described as direct target identification without orthogonal validation.
  • The paper states that the current version intentionally focuses on TPP/PISA-family assays, while other chemoproteomic approaches such as activity-based protein profiling, kinase pulldown methods, LiP-MS, PELSA, pulse proteolysis, and DARTS are future directions. The case-study associations—additional methotrexate-associated proteins, H2AFX shifts, and SCIN candidate compounds—are presented as hypothesis-generating and were not independently validated in the current study.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.mcpro.2026.101603

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Graphical abstract
Graphical abstract CC BY · PubMed Central
Fig. 1 Schematic representation of the DORSSAA workflow.A, data collection from relevant publications. B, manual data curation and integration into datasets. C, relational database schema design. D, implementation and development of the DORSSAA web application.
Fig. 1 Schematic representation of the DORSSAA workflow.A, data collection from relevant publications. B, manual data curation and integration into datasets. C, relational database schema design. D, implementation and development of the DORSSAA web application.CC BY · PubMed Central
Fig. 2 The DORSSAA web application showcases an intuitive interface divided into three primary tabs: Protein Query, Cell Line Query, and Compound Query. Users can initiate queries by selecting options from dropdown menus for UniProt_IDs, cell lines, and compounds. The main panel features visualizations such as bar charts and volcano plots, offering insights into drug-target interactions and protein-level changes. Below the visualizations, a detailed data table provides comprehensive information on all identified interactions, supporting efficient data exploration and in-depth analysis.
Fig. 2 The DORSSAA web application showcases an intuitive interface divided into three primary tabs: Protein Query, Cell Line Query, and Compound Query. Users can initiate queries by selecting options from dropdown menus for UniProt_IDs, cell lines, and compounds. The main panel features visualizations such as bar charts and volcano plots, offering insights into drug-target interactions and protein-level changes. Below the visualizations, a detailed data table provides comprehensive information on all identified interactions, supporting efficient data exploration and in-depth analysis.CC BY · PubMed Central
Fig. 3 Proof-of-principle retrieval and contextualization of the canonical methotrexate-DHFR interaction using DORSSAA.A, protein Query analysis identified methotrexate-associated proteins, with DHFR showing the strongest signal in the queried A-549 dataset. B, the Compound Query tab shows additional compounds linked to DHFR across studies, illustrating compound-centric exploration. C, enrichment and cross-study views place the canonical methotrexate-DHFR interaction in a broader biological and dataset context. Candidate additional associations are hypothesis-generating and were not independently validated in the current study. DHFR, Dihydrofolate Reductase
Fig. 3 Proof-of-principle retrieval and contextualization of the canonical methotrexate-DHFR interaction using DORSSAA.A, protein Query analysis identified methotrexate-associated proteins, with DHFR showing the strongest signal in the queried A-549 dataset. B, the Compound Query tab shows additional compounds linked to DHFR across studies, illustrating compound-centric exploration. C, enrichment and cross-study views place the canonical methotrexate-DHFR interaction in a broader biological and dataset context. Candidate additional associations are hypothesis-generating and were not independently validated in the current study. DHFR, Dihydrofolate ReductaseCC BY · PubMed Central
Fig. 4 Context-dependent H2AFX stability shifts in AML cell lines visualized using DORSSAA.A, in MOLM-16 cells, sapanisertib was associated with a significant H2AFX stability shift (UniProt P16104; log2 fold change = −1.673; FDR = 0.03993). B, in SKM-1 cells, a significant H2AFX shift was also observed with sapanisertib (log2 fold change = +1.533; p = 0.010). C, in MOLM-16, H2AFX-associated shifts were also observed for other single agents and combinations, including Ruxolitinib-Ulixertinib, LY3009120, Ruxolitinib, and Ulixertinib, each with distinct fold-change and significance values. These patterns are presented as pathway-level, hypothesis-generating observations rather than definitive evidence of direct target engagement.
Fig. 4 Context-dependent H2AFX stability shifts in AML cell lines visualized using DORSSAA.A, in MOLM-16 cells, sapanisertib was associated with a significant H2AFX stability shift (UniProt P16104; log2 fold change = −1.673; FDR = 0.03993). B, in SKM-1 cells, a significant H2AFX shift was also observed with sapanisertib (log2 fold change = +1.533; p = 0.010). C, in MOLM-16, H2AFX-associated shifts were also observed for other single agents and combinations, including Ruxolitinib-Ulixertinib, LY3009120, Ruxolitinib, and Ulixertinib, each with distinct fold-change and significance values. These patterns are presented as pathway-level, hypothesis-generating observations rather than definitive evidence of direct target engagement.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 4 Not valid · 28 Not checked · 89 Own results and interpretations

35 more claims

Create a free account to see all 121 claims and to verify the 44 references still open.

See all claims — free account
  • It may state two separate claims as one. 51
  • Probably not a substantial claim. 52

Create a free account to see these claims.

Citations

Cites

Show all 58 references

Cited by

See all 3

Metadata

Authors
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M.
Affiliations
  • University of Helsinki (FI)
  • Karolinska Institutet (SE)
  • Technical University of Munich (DE)
  • Science for Life Laboratory (SE)
Corresponding author
Jafari, Mohieddin
Venue
Molecular & Cellular Proteomics
Publisher
Elsevier BV
Published
2026-07
Volume
25
Issue
7
Pages
101603
ISSN
1535-9476 (ISSN-L)
OpenAlex
W4390442279
Cited by
3
References
58
Citations by year
2026: 3
FWCI
3.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular & Cellular Proteomics (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Helda - University of Helsinki Institutional Repository (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
  • Tampere University Institutional Repository (Tampere University) (publishedVersion, cc-by)
Funders
  • Swedish Society of Medicine
  • Swedish Research Council
  • Tampere University and Tampere University of Applied Sciences
  • Jane and Aatos Erkko Fundation
  • Research Council for Biosciences and Environment
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
drug-target interactions, thermal proteome profiling, drug-protein interactions, drug target identification, off-target effects, combination therapy, methotrexate, leukemia cell lines, A549 cells, mechanism of action
MeSH terms
A549 Cells, Humans, Methotrexate, Solubility, Proteome, Proteomics, Protein Stability, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay. https://app.cochat.ai/papers/10.1016/j.mcpro.2026.101603
The paper
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M. (2026). DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay. Molecular & Cellular Proteomics. https://doi.org/10.1016/j.mcpro.2026.101603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.